Promis Neurosciences Stock Net Income
| 23J Stock | EUR 13.30 0.50 3.62% |
As of the 21st of February, Promis Neurosciences holds the Semi Deviation of 4.63, risk adjusted performance of 0.1183, and Coefficient Of Variation of 696.5. Promis Neurosciences technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices. Please check Promis Neurosciences downside deviation, standard deviation, information ratio, as well as the relationship between the coefficient of variation and variance to decide if Promis Neurosciences is priced some-what accurately, providing market reflects its current price of 13.3 per share.
Promis Neurosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Promis Neurosciences' valuation are provided below:Gross Profit -28.3 M | Market Capitalization 725.5 K | Enterprise Value Revenue 2.2 K | Revenue | Earnings Share (16.85) |
Promis |
Promis Neurosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Promis Neurosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Promis Neurosciences.
| 11/23/2025 |
| 02/21/2026 |
If you would invest 0.00 in Promis Neurosciences on November 23, 2025 and sell it all today you would earn a total of 0.00 from holding Promis Neurosciences or generate 0.0% return on investment in Promis Neurosciences over 90 days. Promis Neurosciences is related to or competes with Samsung Electronics, WOORI FIN, POSCO Holdings, Toyota, MEBUKI FINANCIAL, Fukuoka Financial, and LG Electronics. ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative di... More
Promis Neurosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Promis Neurosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Promis Neurosciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.15 | |||
| Information Ratio | 0.1311 | |||
| Maximum Drawdown | 37.95 | |||
| Value At Risk | (7.41) | |||
| Potential Upside | 14.77 |
Promis Neurosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Promis Neurosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Promis Neurosciences' standard deviation. In reality, there are many statistical measures that can use Promis Neurosciences historical prices to predict the future Promis Neurosciences' volatility.| Risk Adjusted Performance | 0.1183 | |||
| Jensen Alpha | 0.9808 | |||
| Total Risk Alpha | 0.3208 | |||
| Sortino Ratio | 0.138 | |||
| Treynor Ratio | (1.06) |
Promis Neurosciences February 21, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1183 | |||
| Market Risk Adjusted Performance | (1.05) | |||
| Mean Deviation | 4.54 | |||
| Semi Deviation | 4.63 | |||
| Downside Deviation | 6.15 | |||
| Coefficient Of Variation | 696.5 | |||
| Standard Deviation | 6.48 | |||
| Variance | 41.94 | |||
| Information Ratio | 0.1311 | |||
| Jensen Alpha | 0.9808 | |||
| Total Risk Alpha | 0.3208 | |||
| Sortino Ratio | 0.138 | |||
| Treynor Ratio | (1.06) | |||
| Maximum Drawdown | 37.95 | |||
| Value At Risk | (7.41) | |||
| Potential Upside | 14.77 | |||
| Downside Variance | 37.87 | |||
| Semi Variance | 21.42 | |||
| Expected Short fall | (6.07) | |||
| Skewness | 0.5231 | |||
| Kurtosis | 1.63 |
Promis Neurosciences Backtested Returns
Promis Neurosciences is slightly risky given 3 months investment horizon. Promis Neurosciences maintains Sharpe Ratio (i.e., Efficiency) of 0.19, which implies the firm had a 0.19 % return per unit of risk over the last 3 months. We were able to interpolate twenty-seven different technical indicators, which can help you to evaluate if expected returns of 1.21% are justified by taking the suggested risk. Use Promis Neurosciences Semi Deviation of 4.63, coefficient of variation of 696.5, and Risk Adjusted Performance of 0.1183 to evaluate company specific risk that cannot be diversified away. Promis Neurosciences holds a performance score of 15 on a scale of zero to a hundred. The company holds a Beta of -0.87, which implies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Promis Neurosciences are expected to decrease slowly. On the other hand, during market turmoil, Promis Neurosciences is expected to outperform it slightly. Use Promis Neurosciences downside deviation, information ratio, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to analyze future returns on Promis Neurosciences.
Auto-correlation | -0.18 |
Insignificant reverse predictability
Promis Neurosciences has insignificant reverse predictability. Overlapping area represents the amount of predictability between Promis Neurosciences time series from 23rd of November 2025 to 7th of January 2026 and 7th of January 2026 to 21st of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Promis Neurosciences price movement. The serial correlation of -0.18 indicates that over 18.0% of current Promis Neurosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.18 | |
| Spearman Rank Test | -0.24 | |
| Residual Average | 0.0 | |
| Price Variance | 5.59 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Promis Neurosciences reported net income of 2.78 M. This is 99.19% lower than that of the Biotechnology sector and 96.03% lower than that of the Health Care industry. The net income for all Germany stocks is 99.51% higher than that of the company.
Promis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Promis Neurosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Promis Neurosciences could also be used in its relative valuation, which is a method of valuing Promis Neurosciences by comparing valuation metrics of similar companies.Promis Neurosciences is currently under evaluation in net income category among its peers.
Promis Fundamentals
| Return On Equity | -3.56 | ||||
| Return On Asset | -0.85 | ||||
| Current Valuation | 14.66 M | ||||
| Shares Outstanding | 7.2 M | ||||
| Shares Owned By Insiders | 24.78 % | ||||
| Shares Owned By Institutions | 75.22 % | ||||
| Price To Book | 3.50 X | ||||
| Price To Sales | 4,159 X | ||||
| Gross Profit | (28.34 M) | ||||
| EBITDA | (14.02 M) | ||||
| Net Income | 2.78 M | ||||
| Cash And Equivalents | 21.5 M | ||||
| Cash Per Share | 0.05 X | ||||
| Total Debt | 2.42 M | ||||
| Debt To Equity | 0.66 % | ||||
| Current Ratio | 19.07 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | (27.18 M) | ||||
| Earnings Per Share | (16.85) X | ||||
| Beta | -0.093 | ||||
| Market Capitalization | 725.54 K | ||||
| Total Asset | 18.91 M | ||||
| Retained Earnings | (90.69 M) | ||||
| Working Capital | 16.69 M | ||||
| Net Asset | 18.91 M |
About Promis Neurosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Promis Neurosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Promis Neurosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Promis Neurosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Promis Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. For more detail on how to invest in Promis Stock please use our How to Invest in Promis Neurosciences guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.